Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology

Ameet Patki, Himanshu Bavishi, Chandravati Kumari, Jayarani Kamraj, M. Venugopal, K. Kunjimoideen, Poornima Nadkarni, Samundi Sankari, Sunil Chaudhary, M. Sangeeta, C. Manjunath, Pratap Kumar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Globally, about 10%-15% couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalJournal of Human Reproductive Sciences
Volume11
Issue number2
DOIs
Publication statusPublished - 01-04-2018

Fingerprint

Assisted Reproductive Techniques
Ovulation Induction
Gonadotropins
Aptitude
Biosimilar Pharmaceuticals
Meta-Analysis
Safety
Costs and Cost Analysis
Multiple Pregnancy
Therapeutics
Infertility
Life Style
Consensus
Clinical Trials
Injections

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine

Cite this

Patki, Ameet ; Bavishi, Himanshu ; Kumari, Chandravati ; Kamraj, Jayarani ; Venugopal, M. ; Kunjimoideen, K. ; Nadkarni, Poornima ; Sankari, Samundi ; Chaudhary, Sunil ; Sangeeta, M. ; Manjunath, C. ; Kumar, Pratap. / Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology. In: Journal of Human Reproductive Sciences. 2018 ; Vol. 11, No. 2. pp. 119-124.
@article{b594b350d6d04ceeb57a6ff21c416653,
title = "Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology",
abstract = "Globally, about 10{\%}-15{\%} couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.",
author = "Ameet Patki and Himanshu Bavishi and Chandravati Kumari and Jayarani Kamraj and M. Venugopal and K. Kunjimoideen and Poornima Nadkarni and Samundi Sankari and Sunil Chaudhary and M. Sangeeta and C. Manjunath and Pratap Kumar",
year = "2018",
month = "4",
day = "1",
doi = "10.4103/jhrs.JHRS_79_17",
language = "English",
volume = "11",
pages = "119--124",
journal = "Journal of Human Reproductive Sciences",
issn = "0974-1208",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Patki, A, Bavishi, H, Kumari, C, Kamraj, J, Venugopal, M, Kunjimoideen, K, Nadkarni, P, Sankari, S, Chaudhary, S, Sangeeta, M, Manjunath, C & Kumar, P 2018, 'Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology', Journal of Human Reproductive Sciences, vol. 11, no. 2, pp. 119-124. https://doi.org/10.4103/jhrs.JHRS_79_17

Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology. / Patki, Ameet; Bavishi, Himanshu; Kumari, Chandravati; Kamraj, Jayarani; Venugopal, M.; Kunjimoideen, K.; Nadkarni, Poornima; Sankari, Samundi; Chaudhary, Sunil; Sangeeta, M.; Manjunath, C.; Kumar, Pratap.

In: Journal of Human Reproductive Sciences, Vol. 11, No. 2, 01.04.2018, p. 119-124.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology

AU - Patki, Ameet

AU - Bavishi, Himanshu

AU - Kumari, Chandravati

AU - Kamraj, Jayarani

AU - Venugopal, M.

AU - Kunjimoideen, K.

AU - Nadkarni, Poornima

AU - Sankari, Samundi

AU - Chaudhary, Sunil

AU - Sangeeta, M.

AU - Manjunath, C.

AU - Kumar, Pratap

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Globally, about 10%-15% couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.

AB - Globally, about 10%-15% couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.

UR - http://www.scopus.com/inward/record.url?scp=85051350576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051350576&partnerID=8YFLogxK

U2 - 10.4103/jhrs.JHRS_79_17

DO - 10.4103/jhrs.JHRS_79_17

M3 - Review article

VL - 11

SP - 119

EP - 124

JO - Journal of Human Reproductive Sciences

JF - Journal of Human Reproductive Sciences

SN - 0974-1208

IS - 2

ER -